Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment

MEK inhibitors for the treatment of non-small cell lung cancer

(2021) Jing Han et al.   Journal of Hematology & Oncology

Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer

(2020) Jiyun Lee et al.   CANCER

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer

(2020) Francesco Facchinetti et al.   EUROPEAN JOURNAL OF CANCER

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

(2019) et al.   JAMA Oncology

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients

(2019) Jemal Hussien Ahmed et al.   Cancers

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer

(2019) Nicolas Guibert et al.   LUNG CANCER

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

(2019) Hyunchul Jung et al.   Nature Communications

GeneFuse: detection and visualization of target gene fusions from DNA sequencing data

(2018) Shifu Chen et al.   International Journal of Biological Sciences

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib

(2018) Daniel L. Abravanel et al.   Journal of Thoracic Oncology

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

(2017) Christopher Abbosh et al.   NATURE

Integrating liquid biopsies into the management of cancer

(2017) Giulia Siravegna et al.   Nature Reviews Clinical Oncology

Copy number variants of ABCF1, IL17REL, and FCGR3A are associated with the risk of gout

(2017) Zheng Dong et al.   Protein & Cell

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

(2016) Haidong Tang et al.   CANCER CELL

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

(2016) J. C. Thompson et al.   CLINICAL CANCER RESEARCH

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

Analysis of protein-coding genetic variation in 60,706 humans

(2016) Monkol Lek et al.   NATURE

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

(2016) Jacob J. Chabon et al.   Nature Communications

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

(2015) C. P. Paweletz et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6andCYP2C19Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

(2015) JK Hicks et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

(2015) David P. Carbone et al.   Journal of Thoracic Oncology

A global reference for human genetic variation

(2015) Richard A. Gibbs et al.   NATURE

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR

(2015) Hui Yang et al.   Nature Protocols

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

(2015) Z. Piotrowska et al.   Cancer Discovery

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Association ofFCGR3AandFCGR3BCopy Number Variations With Systemic Lupus Erythematosus and Rheumatoid Arthritis in Taiwanese Patients

(2014) Ji-Yih Chen et al.   Arthritis & Rheumatology

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

(2013) Kristian Cibulskis et al.   NATURE BIOTECHNOLOGY

Simultaneous detection of single nucleotide polymorphisms and copy number variations in the CYP2D6 gene by multiplex polymerase chain reaction combined with capillary electrophoresis

(2012) Hsiao-Wei Liao et al.   ANALYTICA CHIMICA ACTA

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

(2012) Pengyuan Liu et al.   CARCINOGENESIS

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

(2012) Guangchuang Yu et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer

(2012) C.-Y. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders

(2011) Walter L. Miller et al.   ENDOCRINE REVIEWS

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

(2011) Craig H Mermel et al.   GENOME BIOLOGY

Fast and accurate long-read alignment with Burrows–Wheeler transform

(2010) Heng Li et al.   BIOINFORMATICS

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

(2010) Daniel Morgensztern et al.   Journal of Thoracic Oncology

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS